Background: Many studies report smaller hippocampal and amygdala volumes in posttraumatic stress disorder (PTSD), but findings have not always been consistent. Here, we present the results of a large-scale neuroimaging consortium study on PTSD conducted by the Psychiatric Genomics Consortium (PGC)-Enhancing Neuroimaging Genetics through Meta-Analysis (ENIGMA) PTSD Working Group.
Methods: We analyzed neuroimaging and clinical data from 1868 subjects (794 PTSD patients) contributed by 16 cohorts, representing the largest neuroimaging study of PTSD to date. We assessed the volumes of eight subcortical structures (nucleus accumbens, amygdala, caudate, hippocampus, pallidum, putamen, thalamus, and lateral ventricle). We used a standardized image-analysis and quality-control pipeline established by the ENIGMA consortium.
Results: In a meta-analysis of all samples, we found significantly smaller hippocampi in subjects with current PTSD compared with trauma-exposed control subjects (Cohen's d = -0.17, p = .00054), and smaller amygdalae (d = -0.11, p = .025), although the amygdala finding did not survive a significance level that was Bonferroni corrected for multiple subcortical region comparisons (p < .0063).
Conclusions: Our study is not subject to the biases of meta-analyses of published data, and it represents an important milestone in an ongoing collaborative effort to examine the neurobiological underpinnings of PTSD and the brain's response to trauma.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951719 | PMC |
http://dx.doi.org/10.1016/j.biopsych.2017.09.006 | DOI Listing |
Clin Neuropharmacol
January 2025
Eastern Virginia Medical School, Norfolk, VA.
Objectives: This study reviews literature on the psychiatric effects of delta-8-THC, particularly psychosis and severe mental health outcomes, to highlight the need for further research and regulation.
Background: Marijuana, the most widely used illicit drug in the United States, sees increasing use due to legalization. Although moderate use is generally safe, adverse effects can occur, especially in those with preexisting conditions.
Annu Rev Clin Psychol
January 2025
Department of Psychology, Rutgers, the State University of New Jersey, New Brunswick, New Jersey, USA; email:
Personality traits involving negative affect, as well as mental disorders including depression, anxiety, and posttraumatic stress disorder, are cardiovascular risk factors. However, which of these confer risk independently is uncertain, and the implications of their overlap, combinations, and interactions are poorly understood. Potential explanatory mechanisms are being characterized with increasing detail and sophistication.
View Article and Find Full Text PDFPsychol Trauma
January 2025
Department of Psychological Sciences, University of Missouri-St. Louis.
Objective: Exposure to trauma and subsequent posttraumatic stress symptoms (PTSS) increase the risk of poor physical health outcomes. Yet, the nuances of the paths from trauma to poor health are largely theoretical, and research regarding how trauma types relate to specific trauma-related changes to diet and exercise is needed. The present study examined the associations between noninterpersonal and interpersonal trauma and PTSS with several novel dietary and exercise changes (i.
View Article and Find Full Text PDFPsychol Trauma
January 2025
Institute of Social Sciences, Police Academy.
Objective: Professionals working with people after traumatic events can experience both secondary traumatic stress (STS) and secondary posttraumatic growth (SPTG) as a result of exposure to indirect trauma; in both cases, a key role in their development is played by ruminations about the events experienced by the client. The aim of the study was to establish the relationship between STS, ruminations, and SPTG and determine the mediating role of ruminations in the relationship between STS and SPTG in a group of police officers.
Method: The study examined 682 police officers exposed to indirect trauma.
In August 2024, The U.S. Food and Drug Administration rejected Lykos Therapeutics, Inc.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!